Phase II “Study to Evaluate the Safety and Efficacy of Immune Killer Cells (IKC) in Stage IV Non-sma
Phase II Study to Evaluate the Safety and Efficacy of Immune Killer Cells (IKC®) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Targeted Therapy
Comments